PSMA Theranostics: Current Status and Future Directions
Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases. There is increasing evidence of encouraging response rates and a low toxicity profile of radioligand therapy (RLT) of metast...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2018-06-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.1177/1536012118776068 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832544632124211200 |
|---|---|
| author | Kambiz Rahbar MD Ali Afshar-Oromieh MD Hossein Jadvar MD, PhD Hojjat Ahmadzadehfar MD, MSc |
| author_facet | Kambiz Rahbar MD Ali Afshar-Oromieh MD Hossein Jadvar MD, PhD Hojjat Ahmadzadehfar MD, MSc |
| author_sort | Kambiz Rahbar MD |
| collection | DOAJ |
| description | Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases. There is increasing evidence of encouraging response rates and a low toxicity profile of radioligand therapy (RLT) of metastatic castration-resistant prostate cancer using 177 Lu-labeled PSMA ligands. In this article, we review the current status of diagnostics and therapy using radiolabeled PSMA ligands. We also suggest protocols for patient selection criteria and conduct of PSMA-based RLT. Challenges and opportunities of PSMA theranostics are discussed. |
| format | Article |
| id | doaj-art-a3df84683e1a46f18a558f6e4b314535 |
| institution | Kabale University |
| issn | 1536-0121 |
| language | English |
| publishDate | 2018-06-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Molecular Imaging |
| spelling | doaj-art-a3df84683e1a46f18a558f6e4b3145352025-02-03T10:08:01ZengSAGE PublishingMolecular Imaging1536-01212018-06-011710.1177/1536012118776068PSMA Theranostics: Current Status and Future DirectionsKambiz Rahbar MD0Ali Afshar-Oromieh MD1Hossein Jadvar MD, PhD2Hojjat Ahmadzadehfar MD, MSc3 Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany Department of Nuclear Medicine, Bern University Hospital, Switzerland Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA Department of Nuclear Medicine, University Hospital Bonn, Bonn, GermanyProstate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases. There is increasing evidence of encouraging response rates and a low toxicity profile of radioligand therapy (RLT) of metastatic castration-resistant prostate cancer using 177 Lu-labeled PSMA ligands. In this article, we review the current status of diagnostics and therapy using radiolabeled PSMA ligands. We also suggest protocols for patient selection criteria and conduct of PSMA-based RLT. Challenges and opportunities of PSMA theranostics are discussed.https://doi.org/10.1177/1536012118776068 |
| spellingShingle | Kambiz Rahbar MD Ali Afshar-Oromieh MD Hossein Jadvar MD, PhD Hojjat Ahmadzadehfar MD, MSc PSMA Theranostics: Current Status and Future Directions Molecular Imaging |
| title | PSMA Theranostics: Current Status and Future Directions |
| title_full | PSMA Theranostics: Current Status and Future Directions |
| title_fullStr | PSMA Theranostics: Current Status and Future Directions |
| title_full_unstemmed | PSMA Theranostics: Current Status and Future Directions |
| title_short | PSMA Theranostics: Current Status and Future Directions |
| title_sort | psma theranostics current status and future directions |
| url | https://doi.org/10.1177/1536012118776068 |
| work_keys_str_mv | AT kambizrahbarmd psmatheranosticscurrentstatusandfuturedirections AT aliafsharoromiehmd psmatheranosticscurrentstatusandfuturedirections AT hosseinjadvarmdphd psmatheranosticscurrentstatusandfuturedirections AT hojjatahmadzadehfarmdmsc psmatheranosticscurrentstatusandfuturedirections |